Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
blog-list-cover
Recent blog posts
Opugotamig Biologics Sequence Review Report 2026: Folate receptor alpha Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
Opugotamig Biologics Sequence Review Report 2026: Folate receptor alpha Similarity and Patent-Risk Signals
27 July 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Opugotamig, an antibody targeting Folate receptor alpha.
Read →
Lanerkitug Biologics Sequence Review Report 2026: CCR8 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
Lanerkitug Biologics Sequence Review Report 2026: CCR8 Similarity and Patent-Risk Signals
27 July 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Lanerkitug, an antibody targeting CCR8.
Read →
Mipletamig Biologics Sequence Review Report 2026: IL3RA × CD3E Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
Mipletamig Biologics Sequence Review Report 2026: IL3RA × CD3E Similarity and Patent-Risk Signals
27 July 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Mipletamig, an antibody targeting IL3RA × CD3E.
Read →
Precemtabart Biologics Sequence Review Report 2026: CEACAM5 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
Precemtabart Biologics Sequence Review Report 2026: CEACAM5 Similarity and Patent-Risk Signals
27 July 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Precemtabart, an antibody targeting CEACAM5.
Read →
Ragistomig Biologics Sequence Review Report 2026: PD-L1 × 4-1BB Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
Ragistomig Biologics Sequence Review Report 2026: PD-L1 × 4-1BB Similarity and Patent-Risk Signals
27 July 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Ragistomig, an antibody targeting PD-L1 × 4-1BB.
Read →
Lumistobart Biologics Sequence Review Report 2026: SIRPA Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
Lumistobart Biologics Sequence Review Report 2026: SIRPA Similarity and Patent-Risk Signals
27 July 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Lumistobart, an antibody targeting SIRPA.
Read →
Lancastotug Biologics Sequence Review Report 2026: TIGIT Similarity and Patent-Risk Signals
8 min read
Lancastotug Biologics Sequence Review Report 2026: TIGIT Similarity and Patent-Risk Signals
27 July 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Lancastotug, an antibody targeting TIGIT.
Read →
Luvagrobart Biologics Sequence Review Report 2026: NGF Similarity and Patent-Risk Signals
8 min read
Luvagrobart Biologics Sequence Review Report 2026: NGF Similarity and Patent-Risk Signals
27 July 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Luvagrobart, an antibody targeting NGF.
Read →
Givastomig Biologics Sequence Review Report 2026: Claudin 18.2 × 4-1BB Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
Givastomig Biologics Sequence Review Report 2026: Claudin 18.2 × 4-1BB Similarity and Patent-Risk Signals
27 July 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Givastomig, an antibody targeting Claudin 18.2 × 4-1BB.
Read →
Etakafusp Biologics Sequence Review Report 2026: CD8 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
Etakafusp Biologics Sequence Review Report 2026: CD8 Similarity and Patent-Risk Signals
27 July 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Etakafusp, an antibody targeting CD8.
Read →
Izastobart Biologics Sequence Review Report 2026: C5AR1 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
Izastobart Biologics Sequence Review Report 2026: C5AR1 Similarity and Patent-Risk Signals
27 July 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Izastobart, an antibody targeting C5AR1.
Read →
Calotatug Biologics Sequence Review Report 2026: HER2 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
Calotatug Biologics Sequence Review Report 2026: HER2 Similarity and Patent-Risk Signals
27 July 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Calotatug, an antibody targeting HER2.
Read →